503 related articles for article (PubMed ID: 26252258)
1. [Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors in CKD].
Insalaco M; Zanoli L; Rastelli S; Lentini P; Rapisarda F; Fatuzzo P; Castellino P; Granata A
G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252258
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.
Zanoli L; Granata A; Lentini P; Rastelli S; Fatuzzo P; Rapisarda F; Castellino P
ScientificWorldJournal; 2015; 2015():317507. PubMed ID: 25785281
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA
Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
[TBL] [Abstract][Full Text] [Related]
5. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy.
Škrtić M; Cherney DZ
Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):96-103. PubMed ID: 25470017
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 inhibitors.
Dardi I; Kouvatsos T; Jabbour SA
Biochem Pharmacol; 2016 Feb; 101():27-39. PubMed ID: 26362302
[TBL] [Abstract][Full Text] [Related]
8. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.
Opie LH
Cardiovasc Drugs Ther; 2014 Aug; 28(4):331-4. PubMed ID: 24825435
[TBL] [Abstract][Full Text] [Related]
9. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus.
Brunton SA
Int J Clin Pract; 2015 Oct; 69(10):1071-87. PubMed ID: 26147213
[TBL] [Abstract][Full Text] [Related]
10. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
[TBL] [Abstract][Full Text] [Related]
11. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
Bailey CJ; Day C; Bellary S
Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
13. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
14. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
15. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
[TBL] [Abstract][Full Text] [Related]
16. Renal safety profile of sodium-glucose cotransporter-2 inhibitors and other safety data.
Gómez-Fernández P; Fernández-García D
Med Clin (Barc); 2016 Nov; 147 Suppl 1():44-48. PubMed ID: 28760225
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
18. Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Tsimihodimos V; Filippatos TD; Elisaf MS
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):399-408. PubMed ID: 27819144
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibitors in the treatment of type 2 diabetes.
Hasan FM; Alsahli M; Gerich JE
Diabetes Res Clin Pract; 2014 Jun; 104(3):297-322. PubMed ID: 24735709
[TBL] [Abstract][Full Text] [Related]
20. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
